Pancreatic Cancer Research

Clinical trialEarly Phase 1Terminated

High Dose Omeprazole in Patients With Pancreatic Cancer

A Phase 0 Study of High Dose Omeprazole in Patients With Pancreatic Cancer Planning to Undergo Surgical Therapy for Evaluating Changes of Biomarkers

Outcome
Stopped earlyTranslational scientist left university (Other)
Phase
Early Phase 1
Status
Terminated
Study type
Interventional
Start
7 September 2021
Ended
3 April 2026
Enrollment
25 participants
Sites
1
Primary outcomes
Proportion; Safety and Tolerability
Sponsor type
Academic / other
Results posted
No
Last update
1 June 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

During this study patients will receive treatment of omeprazole at the dose depending on group enrollment * Group A will receive omeprazole 80 mg, twice a day for 12-14 days unless unacceptable toxicity * Group B, will receive omeprazole 20 mg, once a day for 12-14 days Patients will receive treatment for 2\~3 weeks during the study, and 2 months of follow up. Total accrual is anticipated to take 2 years.